Antisense Oligonucleotides for Neurodegenerative Diseases
Overview
flowchart TD
Antisense_Oligonucleotides_for["Antisense Oligonucleotides for Neurodegenerative"]
Antisense_Oligonucleotides_for["Neurodegenerative"]
Antisense_Oligonucleotides_for -->|"related to"| Antisense_Oligonucleotides_for
style Antisense_Oligonucleotides_for fill:#81c784,stroke:#333,color:#000
Antisense_Oligonucleotides_for["table"]
Antisense_Oligonucleotides_for -->|"related to"| Antisense_Oligonucleotides_for
style Antisense_Oligonucleotides_for fill:#81c784,stroke:#333,color:#000
Antisense_Oligonucleotides_for["class"]
Antisense_Oligonucleotides_for -->|"related to"| Antisense_Oligonucleotides_for
style Antisense_Oligonucleotides_for fill:#81c784,stroke:#333,color:#000
style Antisense_Oligonucleotides_for fill:#4fc3f7,stroke:#333,color:#000
<table class="infobox infobox-therapeutic">
...
Antisense Oligonucleotides for Neurodegenerative Diseases
Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-therapeutic">
Antisense oligonucleotides (ASOs) are short, synthetic single-stranded DNA sequences that bind to specific messenger RNA (mRNA) targets through Watson-Crick base pairing, enabling precise control of protein production. This technology has emerged as a powerful platform for treating neurodegenerative diseases, with tofersen (Qalsody) becoming the first FDA-approved ASO for a neurodegenerative disease in 2023[@fda2023]. By directly modulating RNA, ASOs can reduce toxic protein levels, restore normal splicing patterns, and increase expression of protective protein variants—offering a complementary approach to antibodies and small molecules.
Mechanism of Action ASOs employ two primary mechanisms:
ASO binds to complementary mRNA
Forms RNA-DNA hybrid recognized by RNase H1
RNase H cleaves the RNA strand
Result: Reduced protein production from target mRNA
Splicing Modulation
ASO binds to pre-mRNA at specific sites
Masks or reveals splice sites
Alters exon inclusion/skipping
Result: Different protein isoforms produced
Additional Mechanisms
Steric blockade of translation initiation
Interference with RNA processing
miRNA sponges (specific ASO designs)
Clinical Programs
Approved Therapies Tofersen (Qalsody) - FDA Approved 2023
Target: SOD1 mRNA
Indication: SOD1-associated Amyotrophic Lateral Sclerosis (ALS)
Manufacturer: Biogen/Ionis
Efficacy: 36% reduction in SOD1 protein, positive trend in clinical endpoints[@miller2023]
Status: First ASO approved for neurodegenerative disease
Nusinersen (Spinraza)
Target: SMN2 pre-mRNA
Indication: Spinal Muscular Atrophy (SMA)
Manufacturer: Biogen/Ionis
Efficacy: Landmark approval, dramatically improved outcomes in infants and children
Note: While SMA is not classic neurodegeneration, validates platform
Key Development Programs
Notable Programs IONIS-MAPTRx (BIIB080)
Reduces production of all tau isoforms
Phase 1/2 showed dose-dependent reduction in cerebrospinal fluid tau[@ionis2021]
Potential for both Alzheimer's and 4R tauopathies (PSP, CBD)
Partnered with Biogen
IONIS-HTTRx (RO7234292)
Lowers mutant [huntingtin protein](/proteins/huntingtin)
Phase 1/2 showed 40-60% reduction in CSF huntingtin[@tabrizi2019]
First demonstration of huntingtin lowering in humans
Partnered with Roche
C9orf72 Programs
Target repeat-containing RNA from expanded C9orf72 gene
Most common genetic cause of ALS and FTD
Multiple programs in early development
Advantages
Precise Target Engagement
Direct binding to specific RNA sequences
Can target any gene with known sequence
Predictable dose-response relationship
CNS Delivery
Systemically administered ASOs reach the brain and spinal cord
Distribution to multiple brain regions
Particularly good reach to spinal cord (relevant for ALS, SMA)
Reversible Effects
Protein levels return to baseline after stopping treatment
Allows treatment interruption if needed
Useful for safety assessment
Modular Design
ASO chemistry can be optimized for each target
Gapmer design for RNase H activity
Steric-blocking ASOs for splicing modulation
Proven Regulatory Path
Multiple approvals in neurological diseases
Established regulatory frameworks
Clear development pathways
Limitations
Off-Target Effects
Sequences with partial complementarity may be affected
Requires careful sequence optimization
Careful safety monitoring required
Repeat Dosing
Most ASOs require monthly to quarterly administration
Long-term treatment burden
Patient compliance considerations
Cell-Type Specificity
Distribution largely to glial cells
Limited neuronal uptake
May require engineering for specific populations
Safety Monitoring
Liver function monitoring required
Platelet count monitoring
Potential for thrombocytopenia
Cost
Annual treatment costs exceed $100,000
Similar to antibody therapies
Long-term financial burden
Chemistry and Design
First-Generation ASOs
Phosphorothioate backbone
First clinical ASOs (Fomivirsen)
Higher nuclease resistance than natural DNA
Second-Generation ASOs
2'-O-methyl or 2'-O-methoxyethyl modifications
Improved affinity and stability
Reduced toxicity
Third-Generation ASOs
Gapmer design: 2'-modified wings, DNA gap
Maximizes RNase H activity
Currently most advanced in clinic
Stereopure ASOs
Defined stereochemistry at each chiral center
Improved potency and safety
Used by Wave Life Sciences
Future Directions
Enhanced Delivery
Conjugates for receptor-mediated uptake
Brain-penetrant ASOs
Cell-type specific targeting
Combination Approaches
ASO + antibody therapy
ASO + small molecule
Multiple ASOs targeting different pathways
New Targets
[TDP-43](/mechanisms/tdp-43-proteinopathy) proteinopathies
RNA foci in repeat expansion diseases
Non-coding RNAs
Cross-Links
[Therapeutic Modalities Overview](/therapeutics/therapeutic-modalities)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Tau Protein](/proteins/tau)
[Huntingtin Protein](/proteins/huntingtin-protein)
[Tofersen](/therapeutics/tofersen)
See Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Unknown, FDA. (2023). FDA approves treatment for amyotrophic lateral sclerosis (2023)
[Miller, T., et al, (2023) (2023)](https://doi.org/10.1056/NEJMoa2304632)
Unknown, Ionis Pharmaceuticals. (2021). IONIS-MAPTRx demonstrates dose-dependent reduction of tau protein in phase 1/2 study (2021)
[Tabrizi, S. J., et al., (2019). Targeting huntingtin expression in patients with Huntington's disease (2019)](https://doi.org/10.1056/NEJMoa1900907) Show full description